Healthy Volunteers
Conditions
Brief summary
The main purpose of the study is to evaluate the absorption of omega-3 fatty acids into the blood following consumption of krill oil compared with fish oil and placebo.
Detailed description
The main purpose of the study is to evaluate the absorption of omega-3 fatty acids into the blood following consumption of krill oil compared with fish oil and placebo. An additional purpose is to evaluate the lipid-lowering efficacy and safety of consumption of Krill Oil and Fish Oil to a placebo product. It has been shown that the ingestion of Krill Oil leads to better absorption of omega-3 fatty acids compared to ingestion of Fish Oil. It was also shown that consumption of krill oil and fish oil result in a favorable modification of lipid profiles. Therefore, it is anticipated that consumption of these krill oil and fish oil will improve lipid profile, as well as other health-related markers and will be safe and well tolerated.
Interventions
DIETARY_SUPPLEMENTKrill oil
Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
DIETARY_SUPPLEMENTFish Oil
Fish oil: Total omega-3 fatty acids: 560-660 mg
Sponsors
Enzymotec
University of Manitoba
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy men and premenopausal not pregnant or nursing women between 18 and 49 years old.
Exclusion criteria
* smokers * rheumatoid arthritis * chronic illness * cardiovascular problems * dyslipidemia * liver and kidney disease * diabetes * endocrine or metabolic disease * inflammatory bowel disease * pancreatitis * gallbladder or biliary disease * neurological/psychological disease * bleeding disorders * experienced platelet abnormalities * gastrointestinal disorders that could interfere with fat absorption * hypertension * history of cancer * an intention to lose weight * use of anticoagulant * serum triglycerides (TG) \>200 mg/dL, and/or total cholesterol (TC) \>240 mg/dL, and/or LDL-cholesterol (LDL-C) \>160 mg/dL * hypertension or lipid lowering medications * consumption of more than one alcoholic drinks/day * Consumption of more than one fish or seafood serving * one month prior to the start of the study * omega-6 fatty acids in the past 6 months * planned to consume seafood products or fish or to use any omega-3 or omega-6 fatty acids nutritional supplements at anytime in the duration of the study * planned to to become pregnant during the study period * BMI\>28 * allergies to fish seafood or corn
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bioavailability | 1 month |
Countries
Canada
Outcome results
None listed